|Bid||12.25 x 100|
|Ask||14.00 x 1500|
|Day's Range||12.36 - 12.79|
|52 Week Range||11.30 - 67.90|
|PE Ratio (TTM)||3.90|
|Earnings Date||Nov 7, 2017 - Nov 13, 2017|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||15.00|
ISIN No. US590328AA86) (the "Notes"), which amount reflects the consummation of the purchase of the Notes from the Settlement Noteholders (as defined herein) pursuant to the Settlement Agreement (as defined herein). The Company agreed to conduct the Tender Offer in connection with the settlement agreement (the "Settlement Agreement") that it entered into on October 6, 2017 with Wolverine Flagship Fund Trading Limited, 1992 MSF International Ltd. and 1992 Tactical Credit Master Fund, L.P. (collectively, the "Settlement Noteholders") and Wells Fargo Bank, National Association (the "Trustee") to resolve the lawsuit pending in the Court of Chancery in the State of Delaware captioned Wells Fargo Bank, N.A., et al. v. Merrimack Pharmaceuticals, Inc., C.A. No. 2017-0199-JTL filed by the Settlement Noteholders and the Trustee.
If you are a shareholder in Merrimack Pharmaceuticals Inc’s (NASDAQ:MACK), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...
CAMBRIDGE, Mass., Oct. 10, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (MACK) today announced that it has reached a settlement agreement with Wolverine Flagship Fund Trading Limited, 1992 MSF International Ltd. and 1992 Tactical Credit Master Fund, L.P. (collectively, "Noteholder Plaintiffs") and Wells Fargo Bank, National Association, to resolve the previously disclosed lawsuit captioned Wells Fargo Bank, N.A., et. al. v. Merrimack Pharmaceuticals, Inc. pending in the Court of Chancery in the State of Delaware (the "Delaware Action").
Merrimack Pharmaceuticals Inc (NASDAQ:MACK), a pharmaceuticals, biotechnology and life sciences company based in United States, saw a significant share price rise of over 20% in the past couple of monthsRead More...
NEW YORK, NY / ACCESSWIRE / September 7, 2017 / After posting the worst daily drop in weeks on rising geopolitical tensions between North Korea and the from their worst daily drop in weeks, U.S. markets ...
Otonomy shares rose in premarket trading on Aug. 31 after plunging Wednesday on the heels of disappointing data in a Phase 3 study of Otividex in patients with Meniere's disease.
CAMBRIDGE, Mass., Aug. 31, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (MACK) today announced that the previously disclosed one-for-ten reverse stock split of its issued and outstanding common stock will be effective for trading purposes as of the commencement of trading on September 6, 2017. Merrimack's stockholders approved an amendment to the Company's certificate of incorporation to effect the reverse stock split at the Annual Meeting of Stockholders on August 11, 2017.
CAMBRIDGE, Mass., Aug. 14, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (MACK) today announced that it has strengthened its executive management team with the appointment of Jean M. Franchi as Chief Financial Officer, effective August 21, 2017. In this role, Ms. Franchi will plan and oversee Merrimack's financial strategy to support the ongoing development of multiple clinical- and preclinical-stage product candidates for cancer. Over the course of a 30-year career in the biotechnology and life sciences sectors, Ms. Franchi has held senior financial management roles at several leading companies spanning all stages of development, from research to commercial.
Merrimack Pharmaceuticals (MACK) reported wider-than-expected loss in the second quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.
The Cambridge, Massachusetts-based company said it had profit of $3.86 per share. Losses, adjusted to account for discontinued operations, were 22 cents per share. The results did not meet Wall Street ...
- Announced hiring of industry veterans Dr. Sergio Santillana as Chief Medical Officer and Thomas Needham as Chief Business Officer to bolster executive team - - Phase 2 CARRIE study of MM-141 completed ...
NEW YORK, NY / ACCESSWIRE / August 9, 2017 / Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) will be discussing their earnings results in their Q2 Earnings Call to be held on Wednesday, August 9, 2017 ...
The call will cover an update on Merrimack's recent progress as well as a summary of second quarter 2017 financial results. A listen-only webcast of the call will be available in the Investors section of Merrimack's website, investors.merrimack.com, and a replay of the call will be archived there for six weeks. Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Merrimack Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to MACK-US. Comparing the performance and risk of Merrimack Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Sales of Merrimack Pharmaceuticals, Inc???s (MACK) only approved product, Onivyde to Ipsen is expected to bring in $450 million this quarter.
CAMBRIDGE, Mass., July 24, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (MACK) today announced further expansion of its executive management team with the appointment of Thomas E. Needham, Jr., M.B.A., to the position of Chief Business Officer. In this role, Mr. Needham will help design and implement Merrimack's strategy for its broad pipeline of clinical and preclinical development assets. Mr. Needham comes to Merrimack with 25 years of experience in corporate strategy, finance and executive management for public and private biotechnology companies.
NEW YORK, NY / ACCESSWIRE / June 22, 2017 / The Biotech Industry has continued to outperform the broader markets in 2017. Biotech companies appear to be benefitting from a speedier FDA approval process ...
Disappointing trials from XBiotech, Merrimack Pharmaceuticals, and NewLink Genetics have earned the market's ire. But are their declines overdone?
Merrimack Pharmaceuticals announced completion of enrollment in the ongoing phase II study, evaluatingMM-141 in combination with standard of care for treatment of patients with previously untreated metastatic pancreatic cancer.
CAMBRIDGE, Mass., June 19, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK) today announced that it has enrolled the last patient in the ongoing CARRIE study, a Phase 2, double-blind, placebo-controlled, randomized trial, evaluating MM-141 (istiratumab) in combination with standard of care in previously untreated patients with metastatic pancreatic cancer. MM-141 is a bispecific antibody targeting both the Insulin Like Growth Factor 1 Receptor (IGF-1R) and the HER3 receptor, and is a potent inhibitor of the PI3K/AKT/mTOR signaling pathway. "Today, as we recognize the 10th anniversary of the National Pancreatic Cancer Advocacy Day, we are marking a significant milestone with the CARRIE study, which reflects both the significant need for new therapies in metastatic pancreatic cancer and the potential of MM-141 to play a critical role in addressing that need," said Richard Peters, M.D., Ph.D., President and Chief Executive Officer of Merrimack.
Merrimack (MACK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CAMBRIDGE, Mass., June 8, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced the expansion of its senior management team through the addition of two new executive hires. ...